Welcome to Glycotope

Targeting tumor-specific glycosylation patterns to enable advanced therapies

We are Glycotope

We are dedicated to improving the lives of cancer patients by enabling treatment options that go beyond today’s standard of care.

With exceptional experience in glycobiology and therapeutic antibody development, our mission is to develop advanced biologics that facilitate novel approaches to cancer therapies.

Setting new standards of tumor-specificity in antibody therapeutics

About Us

Learn More about Glycotope and our Leadership Team

Learn more

Technology

Our proprietary technology platform enables the development of antibodies with unrivaled tumor-specificity

Learn more

Pipeline

Our pipeline of antibody therapeutics includes in-house and partnered pre-clinical programs

Learn more

Partners

We aim to continuously expand our collaborations with industry partners and academic centers to further exploit the unique potential of our technology

Learn more

News

8. April 2022
Glycotope Presents New Data on Antibodies and Fusion-Proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) Meeting
Read Article
24. March 2022
Glycotope Announces New Strategy to Maximize Potential of Uniquely-Tumor Specific Antibody Platform
Read Article
1. February 2022
Glycotope to spin-out its Service Business to the newly formed FyoniBio GmbH
Read Article
Read All